Advertisement

Hereditary Angioedema During Pregnancy

Considerations in Management
Published:October 27, 2022DOI:https://doi.org/10.1016/j.iac.2022.05.011

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Immunology and Allergy Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Busse P.J.
        • Christiansen S.C.
        Hereditary angioedema.
        N Engl J Med. 2020; 382: 1136-1148
        • Bork K.
        • Meng G.
        • Staubach P.
        • et al.
        Hereditary angioedema: new findings concerning symptoms, affected organs, and course.
        Am J Med. 2006; 119: 267-274
        • Proper S.P.
        • Lavery W.J.
        • Bernstein J.A.
        Definition and classification of hereditary angioedema.
        Allergy Asthma Proc. 2020; 41: S03-S07
        • Riedl M.A.
        Hereditary angioedema with normal C1-INH (HAE type III).
        J Allergy Clin Immunol Pract. 2013; 1: 427-432
        • Magerl M.
        • Germenis A.E.
        • Maas C.
        • et al.
        Hereditary angioedema with normal C1 inhibitor: update on evaluation and treatment.
        Immunol Allergy Clin N Am. 2017; 37: 571-584
        • Veronez C.L.
        • Csuka D.
        • Sheikh F.R.
        • et al.
        The expanding spectrum of mutations in hereditary angioedema.
        J Allergy Clin Immunol Pract. 2021; 9: 2229-2234
        • Bork K.
        • Staubach P.
        • Hardt J.
        Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angioedema.
        Allergy. 2008; 63: 751-757
        • Bork K.
        • Meng G.
        • Staubach P.
        • et al.
        Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema.
        Transfusion. 2005; 45: 1774-1784
        • Hahn J.
        • Hoess A.
        • Friedrich D.T.
        • et al.
        Unnecessary abdominal interventions in patients with hereditary angioedema.
        J Dtsch Dermatol Ges. 2018; 16: 1443-1449
        • Bork K.
        • Hardt J.
        • Witzke G.
        Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency.
        J Allergy Clin Immunol. 2012; 130: 692-697
        • Minafra F.G.
        • Gonçalves T.R.
        • Alves T.M.
        • et al.
        The mortality from hereditary angioedema worldwide: a review of the real-world data literature.
        Clin Rev Allergy Immunol. 2021; 62: 232-239
        • Kaplan A.P.
        • Joseph K.
        Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade.
        Immunol Allergy Clin N Am. 2017; 37: 513-525
        • Sharma J.
        • Jindal A.K.
        • Banday A.Z.
        • et al.
        Pathophysiology of hereditary angioedema (HAE) beyond the SERPING1 gene.
        Clin Rev Allergy Immunol. 2021; 60: 305-315
        • de Maat S.
        • Björkqvist J.
        • Suffritti C.
        • et al.
        Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
        J Allergy Clin Immunol. 2016; 138: 1414-1423
        • Bork K.
        • Wulff K.
        • Steinmüller-Magin L.
        • et al.
        Hereditary angioedema with a mutation in the plasminogen gene.
        Allergy. 2018; 73: 442-450
        • Bork K.
        • Wulff K.
        • Rossmann H.
        • et al.
        Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin.
        Allergy. 2019; 74: 2479-2481
        • Bork K.
        • Wulff K.
        • Möhl B.S.
        • et al.
        Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation.
        J Allergy Clin Immunol. 2021; 148: 1041-1048
        • Bafunno V.
        • Firinu D.
        • D'Apolito M.
        • et al.
        Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema.
        J Allergy Clin Immunol. 2018; 141: 1009-1017
        • Ariano A.
        • D'Apolito M.
        • Bova M.
        • et al.
        A myoferlin gain-of-function variant associates with a new type of hereditary angioedema.
        Allergy. 2020; 75: 2989-2992
        • Caballero T.
        Treatment of hereditary angioedema.
        J Investig Allergol Clin Immunol. 2021; 31: 1-16
        • Christiansen S.C.
        • Zuraw B.L.
        Hereditary angioedema: on-demand treatment of angioedema attacks.
        Allergy Asthma Proc. 2020; 41: S26-S29
        • Li H.H.
        Hereditary angioedema: long-term prophylactic treatment.
        Allergy Asthma Proc. 2020; 41: S35-S37
        • Craig T.J.
        • Levy R.J.
        • Wasserman R.L.
        • et al.
        Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
        J Allergy Clin Immunol. 2009; 124: 801-808
        • Zuraw B.
        • Cicardi M.
        • Levy R.J.
        • et al.
        Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.
        J Allergy Clin Immunol. 2010; 126: 821-827
        • Cicardi M.
        • Banerji A.
        • Bracho F.
        • et al.
        Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
        N Engl J Med. 2010; 363: 532-541
        • Levy R.J.
        • Lumry W.R.
        • McNeil D.L.
        • et al.
        EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
        Ann Allergy Asthma Immunol. 2010; 104: 523-529
        • Zuraw B.L.
        • Busse P.J.
        • White M.
        • et al.
        Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.
        N Engl J Med. 2010; 363: 513-522
        • Longhurst H.
        • Cicardi M.
        • Craig T.
        • et al.
        Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor.
        N Engl J Med. 2017; 376: 1131-1140
        • Banerji A.
        • Riedl M.A.
        • Bernstein J.A.
        • et al.
        Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial.
        JAMA. 2018; 320: 2108-2121
        • Zuraw B.
        • Lumry W.R.
        • Johnston D.T.
        • et al.
        Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial.
        J Allergy Clin Immunol. 2021; 148: 164-172
        • Gelfand J.A.
        • Sherins R.J.
        • Alling D.W.
        • et al.
        Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.
        N Engl J Med. 1976; 295: 1444-1448
        • Riedl M.A.
        Critical appraisal of androgen use in hereditary angioedema: a systematic review.
        Ann Allergy Asthma Immunol. 2015; 114: 281-288
        • Wintenberger C.
        • Boccon-Gibod I.
        • Launay D.
        • et al.
        Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients.
        Clin Exp Immunol. 2014; 178: 112-117
        • Vitrat-Hincky V.
        • Gompel A.
        • Dumestre-Perard C.
        • et al.
        Type III hereditary angio-oedema: clinical and biological features in a French cohort.
        Allergy. 2010; 65: 1331-1336
        • Craig T.
        Triggers and short-term prophylaxis in patients with hereditary angioedema.
        Allergy Asthma Proc. 2020; 41: S30-S34
        • Zanichelli A.
        • Ghezzi M.
        • Santicchia I.
        • et al.
        Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: an observational study.
        PLoS One. 2020; 15e0230128
        • Farkas H.
        • Zotter Z.
        • Csuka D.
        • et al.
        Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor: a long-term survey.
        Allergy. 2012; 67: 1586-1593
        • Germenis A.E.
        • Margaglione M.
        • Pesquero J.B.
        • et al.
        International consensus on the use of genetics in the management of hereditary angioedema.
        J Allergy Clin Immunol Pract. 2020; 8: 901-911
        • Bork K.
        • Wulff K.
        • Witzke G.
        • et al.
        Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations.
        Allergy. 2015; 70: 1004-1012
        • Agostoni A.
        • Ayg.ren-Pursun E.
        • Binkley K.E.
        • et al.
        Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.
        J Allergy Clin Immunol. 2004; 114: S51-S131
        • Busse P.J.
        • Christiansen S.C.
        • Riedl M.A.
        • et al.
        US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema.
        J Allergy Clin Immunol Pract. 2021; 9: 132-150
        • Maurer M.
        • Magerl M.
        • Betschel S.
        • et al.
        The International WAO/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update.
        Allergy. 2022;
        • Betschel S.
        • Badiou J.
        • Binkley K.
        • et al.
        The International/Canadian Hereditary Angioedema Guideline.
        Allergy Asthma Clin Immunol. 2019; 15: 72
        • Pentsuk N.
        • van der Laan J.W.
        An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.
        Birth Defects Res B Dev Reprod Toxicol. 2009; 86: 328-344
        • Gompel A.
        • Fain O.
        • Boccon-Gibod I.
        • et al.
        Exogenous hormones and hereditary angioedema.
        Int Immunopharmacol. 2020; 78: 106080
        • Brooks J.P.
        • Radojicic C.
        • Riedl M.A.
        • et al.
        Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review.
        J Allergy Clin Immunol Pract. 2020; 8: 1875-1880
        • Fox J.
        • Vegh A.B.
        • Martinez-Saguer I.
        • et al.
        Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.
        Allergy Asthma Proc. 2017; 38: 216-221
        • van Veen H.A.
        • Koiter J.
        • Vogelezang C.J.
        • et al.
        Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits.
        J Biotechnol. 2012; 162: 319-326
        • Moldovan D.
        • Bernstein J.A.
        • Hakl R.
        • et al.
        Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy.
        J Allergy Clin Immunol Pract. 2019; 7: 2938-2940
        • Hakl R.
        • Kuklínek P.
        • Krčmová I.
        • et al.
        Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy.
        J Clin Immunol. 2018; 38: 810-815
        • Farkas H.
        • Kőhalmi K.V.
        • Veszeli N.
        • et al.
        First report of icatibant treatment in a pregnant patient with hereditary angioedema.
        J Obstet Gynaecol Res. 2016; 42: 1026-1028
        • Kaminsky L.W.
        • Kelbel T.
        • Ansary F.
        • et al.
        Multiple doses of icatibant used during pregnancy.
        Allergy Rhinol (Providence). 2017; 8: 178-181
        • Zanichelli A.
        • Mansi M.
        • Periti G.
        Icatibant exposure during pregnancy in a patient with hereditary angioedema.
        J Investig Allergol Clin Immunol. 2015; 25: 447-449
      1. Icatibant [package insert].
        (Available at:) (Accessed January 22, 2022)
      2. Ecallantide [package insert].
        (Available at:) (Accessed January 22, 2022)
      3. Lanadelumab [package insert].
        (Available at:) (Accessed January 22, 2022)
      4. Berotralstat [package insert].
        (Available at:) (Accessed January 22, 2022)
        • Schwartz R.
        Ambiguous genitalia in a term female infant due to exposure to danazol in utero.
        Am J Dis Child. 1982; 136: 474
        • Reschini E.
        • Giustina G.
        • D’Alberton A.
        • et al.
        Female pseudohermaphroditism due to maternal androgen administration: 25-year follow-up.
        Lancet. 1985; 1: 1226
        • Dunn C.J.
        • Goa K.L.
        Tranexamic acid: a review of its use in surgery and other indications.
        Drugs. 1999; 57: 1005-1032
      5. Tranexamic acid [package insert].
        (Available at:) (Accessed January 22, 2022)
        • Zanichelli A.
        • Azin G.M.
        • Cristina F.
        • et al.
        Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
        Orphanet J Rare Dis. 2018; 13: 51
        • Riedl M.A.
        • Bygum A.
        • Lumry W.
        • et al.
        Safety and usage of C1-inhibitor in hereditary angioedema: Berinert Registry Data.
        J Allergy Clin Immunol Pract. 2016; 4: 963-971
        • Martinez-Saguer I.
        • Rusicke E.
        • Aygören-Pürsün E.
        • et al.
        Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate.
        Am J Obstet Gynecol. 2010; 203: 131
        • Bouillet L.
        • Longhurst H.
        • Boccon-Gibod I.
        • et al.
        Disease expression in women with hereditary angioedema.
        Am J Obstet Gynecol. 2008; 199: 484
        • Czaller I.
        • Visy B.
        • Csuka D.
        • et al.
        The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey.
        Eur J Obstet Gynecol Reprod Biol. 2010; 152: 44-49
        • Caballero T.
        • Farkas H.
        • Bouillet L.
        • et al.
        International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency.
        J Allergy Clin Immunol. 2012; 129: 308-320
        • Nielsen E.W.
        • Gran J.T.
        • Straume B.
        • et al.
        Hereditary angioedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses.
        J Intern Med. 1996; 239: 119-130
        • Caballero T.
        • Canabal J.
        • Rivero-Paparoni D.
        • et al.
        Management of hereditary angioedema in pregnant women: a review.
        Int J Womens Health. 2014; 6: 839-848
      6. Danazol [package insert].
        (Available at:) (Accessed January 22, 2022)
      7. Drugs and lactation Database (LactMed) [Internet]. National Library of Medicine (US), Bethesda (MD)2021 (2006–. Tranexamic Acid)
        • Farkas H.
        • Martinez-Saguer I.
        • Bork K.
        • et al.
        International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.
        Allergy. 2017; 72: 300-313
        • Pedrosa M.
        • Phillips-Angles E.
        • López-Lera A.
        • et al.
        Complement study versus CINH gene testing for the diagnosis of type I hereditary angioedema in children.
        J Clin Immunol. 2016; 36: 16-18